Physician profile
James Voci
NPI 1366476715
$344,918.01
in general payments reported to CMS, 2019-2025
70 companies · $39K in 2025
The $39K reported for 2025 was more than what 95% of Neurology (Psychiatry & Neurology) providers received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $157K · 2020: $55K · 2021: $30K · 2022: $7,613 · 2023: $28K · 2024: $30K · 2025: $39K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $40K · Consulting Fee: $32K · Travel and Lodging: $11K · Food and Beverage: $11K · Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program: $2,340 · Education: $147.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $39,769.00 |
| Consulting Fee | $32,350.00 |
| Travel and Lodging | $11,140.59 |
| Food and Beverage | $10,712.81 |
| Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program | $2,340.00 |
| Education | $147.21 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $50,775.30 | 2019-2024 | Kisunla, Emgality |
| Biogen, INC. | $46,005.54 | 2019-2025 | Vumerity, Tysabri, Plegridy |
| Teva Pharmaceuticals USA, INC. | $40,340.18 | 2019-2025 | Austedo Xr, Austedo Xr |
| Avanir Pharmaceuticals, INC. | $36,260.92 | 2019-2022 | |
| Emd Serono, INC. | $27,608.31 | 2019-2024 | Evobrutinib, Mavenclad |
| Jazz Pharmaceuticals INC. | $24,866.97 | 2022-2025 | |
| Otsuka America Pharmaceutical, INC. | $21,706.77 | 2023-2025 | Rexulti, Nuedexta |
| Genzyme Corporation | $15,431.94 | 2019-2024 | |
| Eisai INC. | $15,412.22 | 2019-2025 | |
| Allergan, INC. | $13,691.54 | 2019-2021 | |
| Mallinckrodt Enterprises LLC | $10,377.56 | 2019 | |
| Abbvie INC. | $8,197.10 | 2019-2025 | Ubrelvy |
| Biohaven Pharmaceuticals, INC. | $7,273.77 | 2021 | |
| Eli Lilly and Company | $5,439.51 | 2023 | |
| Ucb, INC. | $4,288.04 | 2019-2025 | Briviact, Fintepla, Rystiggo |
Show all 70 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Voci listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.